Cargando…

Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine

A reference standard is needed for quality control of protein subunit SARS-CoV-2 vaccines to meet urgent domestic needs. The Chinese National Institutes for Food and Drug Control (NIFDC) launched a project to establish the first reference material for the protein subunit SARS-CoV-2 vaccine to be use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Fan, An, Chaoqiang, Bian, Lianlian, Wang, Yiping, Zhang, Jialu, Cui, Bopei, He, Qian, Yuan, Yadi, Song, Lifang, Yang, Jinghuan, Yan, Xujia, Xu, Kangwei, Li, Changgui, Yao, Shanshan, Wu, Xing, Mao, Qunying, Liang, Zhenglun, Xu, Miao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841209/ https://www.ncbi.nlm.nih.gov/pubmed/35227521 http://dx.doi.org/10.1016/j.vaccine.2022.02.048

Ejemplares similares

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
por: Zhang, Jialu, et al.
Publicado: (2021)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques
por: He, Qian, et al.
Publicado: (2022)

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates
por: He, Qian, et al.
Publicado: (2022)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

Construction and verification of an infectious cDNA clone of coxsackievirus B5
por: Song, Lifang, et al.
Publicado: (2022)

Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
por: Zhang, Jialu, et al.
Publicado: (2022)

Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard
por: Guan, Lidong, et al.
Publicado: (2023)

A Short 5′triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I
por: Song, Ziyang, et al.
Publicado: (2022)

EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
por: Mao, Qunying, et al.
Publicado: (2016)

COVID-19 vaccines: progress and understanding on quality control and evaluation
por: Mao, Qunying, et al.
Publicado: (2021)

Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains
por: Huo, Yaqian, et al.
Publicado: (2021)

B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates
por: Bai, Yu, et al.
Publicado: (2022)

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
por: Bian, Lianlian, et al.
Publicado: (2021)

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
por: He, Qian, et al.
Publicado: (2021)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine
por: Liu, Dong, et al.
Publicado: (2022)

Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
por: Wang, Yiping, et al.
Publicado: (2023)

Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
por: Liu, Pei, et al.
Publicado: (2021)

Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors
por: Cui, Bopei, et al.
Publicado: (2023)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
por: Liu, Jianyang, et al.
Publicado: (2022)

Development of an ELISA Assay for the Determination of SARS-CoV-2 Protein Subunit Vaccine Antigen Content
por: Han, Lu, et al.
Publicado: (2022)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
por: Du, Ruixiao, et al.
Publicado: (2022)

A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine
por: Bai, Yu, et al.
Publicado: (2023)

Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice
por: Bian, Lianlian, et al.
Publicado: (2022)

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
por: Bian, Lianlian, et al.
Publicado: (2022)

A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5
por: Mao, Qunying, et al.
Publicado: (2018)

Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC
por: Liang, Zhenglun, et al.
Publicado: (2014)

A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3
por: Chen, Pan, et al.
Publicado: (2016)

Research Advances on the Stability of mRNA Vaccines
por: Cheng, Feiran, et al.
Publicado: (2023)

A cross-sectional seroepidemiology study of EV-D68 in China
por: Sun, Shiyang, et al.
Publicado: (2018)

Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD concept
por: Liu, Jianyang, et al.
Publicado: (2023)

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy
por: Hu, Chaoying, et al.
Publicado: (2023)

Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine
por: Li, Changgui, et al.
Publicado: (2015)

Comparing the Primary and Recall Immune Response Induced by a New EV71 Vaccine Using Systems Biology Approaches
por: Shao, Jie, et al.
Publicado: (2015)

Development of a pseudovirus based assay for measuring neutralizing antibodies against coxsackievirus B5
por: Chen, Pan, et al.
Publicado: (2017)

Comparative Analysis of the Immunogenicity and Protective Effects of Inactivated EV71 Vaccines in Mice
por: Mao, Qunying, et al.
Publicado: (2012)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
por: He, Qian, et al.
Publicado: (2022)

Research progress on circular RNA vaccines
por: Bai, Yu, et al.
Publicado: (2023)

The Quantification of Spike Proteins in the Inactivated SARS-CoV-2 Vaccines of the Prototype, Delta, and Omicron Variants by LC–MS
por: Xu, Kangwei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9gln2lij31nkm62stn3v6ir27h